Coya Therapeutics

Company snapshot

Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Coya Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Coya Therapeutics.

1. May 23, 2026 Clinical update

   COYA 302 — Phase 2

View all clinical trial activity →

• What is Coya Therapeutics?

  Coave Therapeutics is a pharma organization headquartered in Paris, FR. It trades on NYSE under ticker COYA. Primary therapeutic focus areas include Amyotrophic Lateral Sclerosis (ALS). NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this

• Is Coya Therapeutics publicly traded?

  Yes. Coya Therapeutics is listed with ticker COYA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Coya Therapeutics develop or market?

  No drug profiles are currently linked to Coya Therapeutics. Pipeline programs may still list investigational assets.

• What are the latest developments for Coya Therapeutics?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Coya Therapeutics focus on?

  Coya Therapeutics focuses on Amyotrophic Lateral Sclerosis (ALS) based on our analysis of their pipeline programs and drug development activities.